Abstract: Objective To analyze the current occurrence and influencing factors of female sexual dysfunction (FSD) in young breast cancer patients during endocrine therapy. Methods A total of 189 young female breast cancer patients who underwent posto-perative adjuvant endocrine therapy in Ruijin Hospital, Shanghai Jiao Tong University School of Medicine from January 2021 to July 2021 were selected as the research subjects. The general information questionnaire, female sexual function index scale (FSFI), body image scale for breast cancer patients (BIS), hospital anxiety and depression scale (HADS), social science research solutions (SSRS) and the revised dyadic adjustment scale (RDAS) were collected and analyzed. Logistic regression was used to analyze the influencing factors of FSD. Results Among 189 young female breast cancer patients, the incidence of FSD was 81.0% (153/189). Multivariable analysis showed that breast reconstruction reduced the risk of FSD, compared with mastectomy (OR=0.243, 95%CI: 0.076-0.779, P=0.017). Posto-perative BIS score≥8 was a protective factor for FSD (OR=0.176, 95%CI: 0.059-0.526,P=0.002). Previous chemotherapy (OR=5.250, 95%CI: 2.065-13.347, P<0.001) and anxiety (OR=6.348, 95%CI: 1.985-20.299, P=0.002) were independent risk factors for FSD. Conclusions Young female breast cancer patients have a higher incidence of FSD during endocrine therapy, especially in the patients who have been treated with chemotherapy, have anxiety disorders and poor body image. It is necessary to pay attention to patients' sexual health issues and strengthen the assessment of patients' sexual function by carrying out targeted intervention.

Key words: Breast cancer, Endocrine therapy, Female sexual dysfunction, Anxiety, Body image